MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'ind'. Sat, 03 Sep 2011 02:58:29 +0100 http://www.medworm.com/index.php?rid=3533840&cid=t_104967_87_f&fid=39187&url=http%3A%2F%2Fgetbetterhealth.com%2Fhow-much-does-a-heart-attack-cost%2F2010.05.04 How much would a heart attack cost you? Quite a bit, according to CBS MoneyWatch.com: According to an article from the National Business Group on Health, the average total [editor's note: lifetime] cost of a severe heart attack -– including direct and indirect costs -– is about $1 million. Direct [lifetime] costs include charges for hospitals, doctors and prescription drugs, while indirect costs include lost productivity and time away from work. The average [lifetime] cost of a less-severe heart attack is about $760,000. Amortized over 20 years, that’s $50,000 per year for a severe heart attack and $38,000 per year for a less-severe heart attack. I’m all for maintaining a healthy lifestyle, but before we get all hot and bothered about performing more testing to “prevent&#... Better Health blogs http://www.medworm.com/rss/comments.php?id=3533840 Tue, 04 May 2010 20:00:00 +0100 3533840 http://www.medworm.com/index.php?rid=3111685&cid=t_104967_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FyruucDZmB2s%2F R&D spending by India’s 25 biggest drugmakers grew nearly 17 percent in 2008-09, with several increasing their investments by over 40 percent, according to a survey by Pharmabiz. Total R&D spending by the drugmakers reached $683 million, or 7.75 percent of their sales, up from 7.6 percent in the previous year. Among those that boosted R&D spending by more than 40 percent during the year were Jubilant Organosys, Matrix, Sun Pharma Advance, Ind-Swift, Stride Arcolab and Piramal Healthcare. But the biggest spender was Ranbaxy, spending a total of $100 million, up 2.4 percent from the previous year. The next biggest spender was Dr Reddy’s Laboratories, then Lupin. The survey also forecasts a growing numbers of Abbreviated New Drug Applications and Drug Master Files in highl... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3111685 Tue, 22 Dec 2009 13:17:13 +0100 3111685 http://www.medworm.com/index.php?rid=512520&cid=t_104967_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F105512879%2Fpfizer_initiates_glaucoma_clin.html Clinical trials for NicOx S.A. (EPA: COX)’s new experimental medicine for the treatment of glaucoma - PF-03187207 - has recently been initiated by Pfizer Inc.  (NYSE: PFE) following USFDA’s approval of its Investigational New Drug (IND) approval for PF-03187207, which then results to a euro 1 million milestone payment from Pfizer to NicOx. PF-03187207 is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which is focused on the research and development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma.Often linked to abnormally high pressure in the eye (IOP), due to blockage or malfunction of the eye's drainage systems, glaucoma is a group of eye diseases which can lead to ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=512520 Sat, 31 Mar 2007 03:29:36 +0100 512520 http://www.medworm.com/index.php?rid=486687&cid=t_104967_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F102844956%2Fmicromet_and_tracon_pharmaceut.html Founded in 2005 by Paramount BioSciences, LLC, TRACON Pharmaceuticals is a privately held biopharmaceutical company focused on the development of products for cancer treatment, including agents that inhibit angiogenesis. Micromet, Inc. on the other hand, is a biopharmaceutical company focused on the development of novel and proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Micromet, Inc. (Nasdaq: MITI) and TRACON Pharmaceuticals, Inc. has agreed on an exclusive worldwide license granting TRACON exclusive worldwide rights to develop and commercialize Micromet's D93 antibody with a novel mode of action for the treatment of cancer. D93 - a recombinant humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor cell growth and metastasis by targ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=486687 Mon, 19 Mar 2007 05:12:59 +0100 486687 http://www.medworm.com/index.php?rid=486691&cid=t_104967_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F102844957%2Fexelixis_submitted_ind_for_can.html Exelixis, Inc. (Nasdaq: EXEL) has recently submitted an investigational new drug (IND) application to the USFDA for its candidate anticancer compound XL147. XL147 is a novel, orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). In human tumors, activation of PI3K is frequent – thereby promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy. According to Gisela M. Schwab, MD, senior vice president and chief medical officer at Exelixis: "A growing body of data indicates that inappropriate activation of the PI3K signaling pathway is a common feature of human tumors and may result from dysregulation at multiple points along the signaling cascade. We are therefore evaluating multiple compounds that ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=486691 Mon, 19 Mar 2007 04:05:29 +0100 486691